nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Lethargy—Capecitabine—colon cancer	0.00328	0.00328	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Irinotecan—colon cancer	0.00326	0.00326	CcSEcCtD
Fosaprepitant—Hyponatraemia—Capecitabine—colon cancer	0.00322	0.00322	CcSEcCtD
Fosaprepitant—Osteoarthritis—Capecitabine—colon cancer	0.00321	0.00321	CcSEcCtD
Fosaprepitant—Cardiac disorder—Vincristine—colon cancer	0.00316	0.00316	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Fluorouracil—colon cancer	0.00316	0.00316	CcSEcCtD
Fosaprepitant—Angiopathy—Vincristine—colon cancer	0.00309	0.00309	CcSEcCtD
Fosaprepitant—Flushing—Irinotecan—colon cancer	0.00308	0.00308	CcSEcCtD
Fosaprepitant—Cardiac disorder—Irinotecan—colon cancer	0.00308	0.00308	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Vincristine—colon cancer	0.00307	0.00307	CcSEcCtD
Fosaprepitant—Angiopathy—Irinotecan—colon cancer	0.00301	0.00301	CcSEcCtD
Fosaprepitant—Immune system disorder—Irinotecan—colon cancer	0.003	0.003	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Irinotecan—colon cancer	0.00299	0.00299	CcSEcCtD
Fosaprepitant—Mental disorder—Vincristine—colon cancer	0.00298	0.00298	CcSEcCtD
Fosaprepitant—Urine output increased—Methotrexate—colon cancer	0.00298	0.00298	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Capecitabine—colon cancer	0.00293	0.00293	CcSEcCtD
Fosaprepitant—Hypokalaemia—Capecitabine—colon cancer	0.00292	0.00292	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00289	0.00289	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00289	0.00289	CcSEcCtD
Fosaprepitant—Flatulence—Irinotecan—colon cancer	0.00285	0.00285	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00283	0.00283	CcSEcCtD
Fosaprepitant—Muscular weakness—Capecitabine—colon cancer	0.00283	0.00283	CcSEcCtD
Fosaprepitant—Abdominal distension—Capecitabine—colon cancer	0.00279	0.00279	CcSEcCtD
Fosaprepitant—Muscle spasms—Irinotecan—colon cancer	0.00278	0.00278	CcSEcCtD
Fosaprepitant—Erythema—Fluorouracil—colon cancer	0.00277	0.00277	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Methotrexate—colon cancer	0.00276	0.00276	CcSEcCtD
Fosaprepitant—Anaemia—Vincristine—colon cancer	0.00274	0.00274	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Irinotecan—colon cancer	0.00268	0.00268	CcSEcCtD
Fosaprepitant—Anaemia—Irinotecan—colon cancer	0.00267	0.00267	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Capecitabine—colon cancer	0.00266	0.00266	CcSEcCtD
Fosaprepitant—Malaise—Irinotecan—colon cancer	0.0026	0.0026	CcSEcCtD
Fosaprepitant—Dysuria—Capecitabine—colon cancer	0.00259	0.00259	CcSEcCtD
Fosaprepitant—Syncope—Irinotecan—colon cancer	0.00259	0.00259	CcSEcCtD
Fosaprepitant—Hypertension—Vincristine—colon cancer	0.00256	0.00256	CcSEcCtD
Fosaprepitant—Anaemia—Fluorouracil—colon cancer	0.00256	0.00256	CcSEcCtD
Fosaprepitant—Loss of consciousness—Irinotecan—colon cancer	0.00254	0.00254	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Capecitabine—colon cancer	0.00253	0.00253	CcSEcCtD
Fosaprepitant—Cough—Irinotecan—colon cancer	0.00252	0.00252	CcSEcCtD
Fosaprepitant—Weight decreased—Capecitabine—colon cancer	0.00251	0.00251	CcSEcCtD
Fosaprepitant—Hypertension—Irinotecan—colon cancer	0.00249	0.00249	CcSEcCtD
Fosaprepitant—Infestation NOS—Capecitabine—colon cancer	0.00247	0.00247	CcSEcCtD
Fosaprepitant—Infestation—Capecitabine—colon cancer	0.00247	0.00247	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.00245	0.00245	CcSEcCtD
Fosaprepitant—Lethargy—Methotrexate—colon cancer	0.00244	0.00244	CcSEcCtD
Fosaprepitant—Discomfort—Irinotecan—colon cancer	0.00243	0.00243	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Vincristine—colon cancer	0.00242	0.00242	CcSEcCtD
Fosaprepitant—Oedema—Vincristine—colon cancer	0.00242	0.00242	CcSEcCtD
Fosaprepitant—Stomatitis—Capecitabine—colon cancer	0.00241	0.00241	CcSEcCtD
Fosaprepitant—Infection—Vincristine—colon cancer	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Urinary tract infection—Capecitabine—colon cancer	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Conjunctivitis—Capecitabine—colon cancer	0.0024	0.0024	CcSEcCtD
Fosaprepitant—Osteoarthritis—Methotrexate—colon cancer	0.00239	0.00239	CcSEcCtD
Fosaprepitant—Nervous system disorder—Vincristine—colon cancer	0.00237	0.00237	CcSEcCtD
Fosaprepitant—Haematuria—Capecitabine—colon cancer	0.00236	0.00236	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Fosaprepitant—Oedema—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Fosaprepitant—Chest pain—Fluorouracil—colon cancer	0.00235	0.00235	CcSEcCtD
Fosaprepitant—Infection—Irinotecan—colon cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Vincristine—colon cancer	0.00234	0.00234	CcSEcCtD
Fosaprepitant—Discomfort—Fluorouracil—colon cancer	0.00233	0.00233	CcSEcCtD
Fosaprepitant—Shock—Irinotecan—colon cancer	0.00232	0.00232	CcSEcCtD
Fosaprepitant—Nervous system disorder—Irinotecan—colon cancer	0.00231	0.00231	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Irinotecan—colon cancer	0.00228	0.00228	CcSEcCtD
Fosaprepitant—Hypotension—Vincristine—colon cancer	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Bradycardia—Capecitabine—colon cancer	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Oedema—Fluorouracil—colon cancer	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Fluorouracil—colon cancer	0.00226	0.00226	CcSEcCtD
Fosaprepitant—Infection—Fluorouracil—colon cancer	0.00224	0.00224	CcSEcCtD
Fosaprepitant—Nervous system disorder—Fluorouracil—colon cancer	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Capecitabine—colon cancer	0.00221	0.00221	CcSEcCtD
Fosaprepitant—Hypotension—Irinotecan—colon cancer	0.0022	0.0022	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Capecitabine—colon cancer	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Insomnia—Vincristine—colon cancer	0.00219	0.00219	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Capecitabine—colon cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Urethral disorder—Capecitabine—colon cancer	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00215	0.00215	CcSEcCtD
Fosaprepitant—Insomnia—Irinotecan—colon cancer	0.00213	0.00213	CcSEcCtD
Fosaprepitant—Hypotension—Fluorouracil—colon cancer	0.00211	0.00211	CcSEcCtD
Fosaprepitant—Decreased appetite—Vincristine—colon cancer	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Dyspnoea—Irinotecan—colon cancer	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Erythema multiforme—Capecitabine—colon cancer	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Somnolence—Irinotecan—colon cancer	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Vincristine—colon cancer	0.00209	0.00209	CcSEcCtD
Fosaprepitant—Fatigue—Vincristine—colon cancer	0.00209	0.00209	CcSEcCtD
Fosaprepitant—Eye disorder—Capecitabine—colon cancer	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Dyspepsia—Irinotecan—colon cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Tinnitus—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Pain—Vincristine—colon cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Constipation—Vincristine—colon cancer	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Cardiac disorder—Capecitabine—colon cancer	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Flushing—Capecitabine—colon cancer	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Decreased appetite—Irinotecan—colon cancer	0.00205	0.00205	CcSEcCtD
Fosaprepitant—Insomnia—Fluorouracil—colon cancer	0.00204	0.00204	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Irinotecan—colon cancer	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Fatigue—Irinotecan—colon cancer	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Pain—Irinotecan—colon cancer	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Constipation—Irinotecan—colon cancer	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Angiopathy—Capecitabine—colon cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Dyspnoea—Fluorouracil—colon cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Somnolence—Fluorouracil—colon cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Immune system disorder—Capecitabine—colon cancer	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Capecitabine—colon cancer	0.002	0.002	CcSEcCtD
Fosaprepitant—Dyspepsia—Fluorouracil—colon cancer	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—colon cancer	0.00198	0.00198	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Vincristine—colon cancer	0.00198	0.00198	CcSEcCtD
Fosaprepitant—Decreased appetite—Fluorouracil—colon cancer	0.00196	0.00196	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Mental disorder—Capecitabine—colon cancer	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Feeling abnormal—Irinotecan—colon cancer	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Malnutrition—Capecitabine—colon cancer	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Erythema—Capecitabine—colon cancer	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—colon cancer	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Pain—Fluorouracil—colon cancer	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Irinotecan—colon cancer	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Body temperature increased—Vincristine—colon cancer	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Abdominal pain—Vincristine—colon cancer	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Flatulence—Capecitabine—colon cancer	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Dysgeusia—Capecitabine—colon cancer	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—colon cancer	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Abdominal pain—Irinotecan—colon cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Body temperature increased—Irinotecan—colon cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Feeling abnormal—Fluorouracil—colon cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Muscle spasms—Capecitabine—colon cancer	0.00186	0.00186	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—colon cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—colon cancer	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.00183	0.00183	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—colon cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Capecitabine—colon cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Urticaria—Fluorouracil—colon cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—colon cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Anaemia—Capecitabine—colon cancer	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Body temperature increased—Fluorouracil—colon cancer	0.00178	0.00178	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vincristine—colon cancer	0.00178	0.00178	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—colon cancer	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Malaise—Capecitabine—colon cancer	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Hypersensitivity—Irinotecan—colon cancer	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Asthenia—Vincristine—colon cancer	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Syncope—Capecitabine—colon cancer	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Palpitations—Capecitabine—colon cancer	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Loss of consciousness—Capecitabine—colon cancer	0.0017	0.0017	CcSEcCtD
Fosaprepitant—Asthenia—Irinotecan—colon cancer	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Cough—Capecitabine—colon cancer	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Hypertension—Capecitabine—colon cancer	0.00167	0.00167	CcSEcCtD
Fosaprepitant—Hypersensitivity—Fluorouracil—colon cancer	0.00166	0.00166	CcSEcCtD
Fosaprepitant—Diarrhoea—Vincristine—colon cancer	0.00166	0.00166	CcSEcCtD
Fosaprepitant—Chest pain—Capecitabine—colon cancer	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Anxiety—Capecitabine—colon cancer	0.00164	0.00164	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—colon cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Discomfort—Capecitabine—colon cancer	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—colon cancer	0.00162	0.00162	CcSEcCtD
Fosaprepitant—Diarrhoea—Irinotecan—colon cancer	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Dry mouth—Capecitabine—colon cancer	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Dizziness—Vincristine—colon cancer	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Pruritus—Fluorouracil—colon cancer	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Oedema—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Fosaprepitant—Infection—Capecitabine—colon cancer	0.00157	0.00157	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—colon cancer	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Dizziness—Irinotecan—colon cancer	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Shock—Capecitabine—colon cancer	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Nervous system disorder—Capecitabine—colon cancer	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—colon cancer	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Diarrhoea—Fluorouracil—colon cancer	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—colon cancer	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Vomiting—Vincristine—colon cancer	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—colon cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Skin disorder—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Rash—Vincristine—colon cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Dermatitis—Vincristine—colon cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Headache—Vincristine—colon cancer	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—colon cancer	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Vomiting—Irinotecan—colon cancer	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—colon cancer	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—colon cancer	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—colon cancer	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Rash—Irinotecan—colon cancer	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Dermatitis—Irinotecan—colon cancer	0.00148	0.00148	CcSEcCtD
Fosaprepitant—Headache—Irinotecan—colon cancer	0.00148	0.00148	CcSEcCtD
Fosaprepitant—Hypotension—Capecitabine—colon cancer	0.00147	0.00147	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—colon cancer	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Nausea—Vincristine—colon cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—colon cancer	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Insomnia—Capecitabine—colon cancer	0.00143	0.00143	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—colon cancer	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Dermatitis—Fluorouracil—colon cancer	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—colon cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—colon cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Dyspnoea—Capecitabine—colon cancer	0.00141	0.00141	CcSEcCtD
Fosaprepitant—Nausea—Irinotecan—colon cancer	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Dyspepsia—Capecitabine—colon cancer	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Decreased appetite—Capecitabine—colon cancer	0.00137	0.00137	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Capecitabine—colon cancer	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Fatigue—Capecitabine—colon cancer	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Pain—Capecitabine—colon cancer	0.00135	0.00135	CcSEcCtD
Fosaprepitant—Constipation—Capecitabine—colon cancer	0.00135	0.00135	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—colon cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—colon cancer	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—colon cancer	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Feeling abnormal—Capecitabine—colon cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—colon cancer	0.0013	0.0013	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Capecitabine—colon cancer	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—colon cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Urticaria—Capecitabine—colon cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Abdominal pain—Capecitabine—colon cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Body temperature increased—Capecitabine—colon cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—colon cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Hypersensitivity—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—colon cancer	0.00115	0.00115	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Asthenia—Capecitabine—colon cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Pruritus—Capecitabine—colon cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—colon cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Diarrhoea—Capecitabine—colon cancer	0.00108	0.00108	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—colon cancer	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—colon cancer	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Fosaprepitant—Dizziness—Capecitabine—colon cancer	0.00104	0.00104	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—colon cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—colon cancer	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—colon cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—colon cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—colon cancer	0.001	0.001	CcSEcCtD
Fosaprepitant—Vomiting—Capecitabine—colon cancer	0.001	0.001	CcSEcCtD
Fosaprepitant—Rash—Capecitabine—colon cancer	0.000995	0.000995	CcSEcCtD
Fosaprepitant—Dermatitis—Capecitabine—colon cancer	0.000994	0.000994	CcSEcCtD
Fosaprepitant—Headache—Capecitabine—colon cancer	0.000988	0.000988	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—colon cancer	0.000968	0.000968	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—colon cancer	0.00096	0.00096	CcSEcCtD
Fosaprepitant—Nausea—Capecitabine—colon cancer	0.000937	0.000937	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—colon cancer	0.000933	0.000933	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—colon cancer	0.000928	0.000928	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—colon cancer	0.000928	0.000928	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—colon cancer	0.000865	0.000865	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—colon cancer	0.000843	0.000843	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—colon cancer	0.000831	0.000831	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—colon cancer	0.000804	0.000804	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—colon cancer	0.000777	0.000777	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—colon cancer	0.000747	0.000747	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—colon cancer	0.00074	0.00074	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—colon cancer	0.00074	0.00074	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—colon cancer	0.000736	0.000736	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—colon cancer	0.000698	0.000698	CcSEcCtD
